Sign in

Research summary ·

Prognostic factors of synchronous endometrial and ovarian cancers: a systematic review and meta-analysis of cohort studies.

Written based on 1 research study on PubMed, searched on 6 Nov 2026.

What was studied

This review pooled cohort studies of patients with joint womb and ovary cancers. It looked for factors that predict survival. Reviewers searched several databases up to April 30, 2026. The studies covered 26,543 patients. Of these, 1,275 had SEOC, the name for these joint cancers.

What they found

Several factors were linked to both overall and disease-free survival. These were lymphovascular space invasion and depth of invasion into the womb wall. They also included tumor grade, stage and endometrioid type. Age and CA-125 level showed no significant link with either measure. Poorer survival went with deep invasion into the womb wall. It also went with stage above 2 and grade above 2. Endometrioid type went with better survival.

What it means for patients

The authors say these factors are linked to survival in this cancer pair. They say endometrioid type goes with better survival than other types. They say timely checks of these factors at diagnosis matter for treatment intensity and follow-up.

Why it is not certain yet

The authors rate the evidence as moderate in certainty. Earlier studies gave mixed findings, with few patients. Links to survival do not show cause. The abstract does not give the size of each effect. A review can only be as good as the studies in it.

Source

Prognostic factors of synchronous endometrial and ovarian cancers: a systematic review and meta-analysis of cohort studies.

PubMed · PMID 42972281

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Endometrial cancer publications
Prognostic factors of synchronous endometrial and ovarian cancers: a systematic review and meta-analysis of cohort studies. · Endometrial cancer news explained – Frontlight Research